197 related articles for article (PubMed ID: 29691234)
1. Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15
Borrelli C; Ricci B; Vulpis E; Fionda C; Ricciardi MR; Petrucci MT; Masuelli L; Peri A; Cippitelli M; Zingoni A; Santoni A; Soriani A
Cancer Immunol Res; 2018 Jul; 6(7):860-869. PubMed ID: 29691234
[TBL] [Abstract][Full Text] [Related]
2. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.
Soriani A; Iannitto ML; Ricci B; Fionda C; Malgarini G; Morrone S; Peruzzi G; Ricciardi MR; Petrucci MT; Cippitelli M; Santoni A
J Immunol; 2014 Jul; 193(2):950-60. PubMed ID: 24913980
[TBL] [Abstract][Full Text] [Related]
3. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.
Soriani A; Zingoni A; Cerboni C; Iannitto ML; Ricciardi MR; Di Gialleonardo V; Cippitelli M; Fionda C; Petrucci MT; Guarini A; Foà R; Santoni A
Blood; 2009 Apr; 113(15):3503-11. PubMed ID: 19098271
[TBL] [Abstract][Full Text] [Related]
4. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.
Zingoni A; Cecere F; Vulpis E; Fionda C; Molfetta R; Soriani A; Petrucci MT; Ricciardi MR; Fuerst D; Amendola MG; Mytilineos J; Cerboni C; Paolini R; Cippitelli M; Santoni A
J Immunol; 2015 Jul; 195(2):736-48. PubMed ID: 26071561
[TBL] [Abstract][Full Text] [Related]
5. High dose CD11c-driven IL15 is sufficient to drive NK cell maturation and anti-tumor activity in a trans-presentation independent manner.
Polansky JK; Bahri R; Divivier M; Duitman EH; Vock C; Goyeneche-Patino DA; Orinska Z; Bulfone-Paus S
Sci Rep; 2016 Jan; 6():19699. PubMed ID: 26822794
[TBL] [Abstract][Full Text] [Related]
6. CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.
Pahl JHW; Koch J; Götz JJ; Arnold A; Reusch U; Gantke T; Rajkovic E; Treder M; Cerwenka A
Cancer Immunol Res; 2018 May; 6(5):517-527. PubMed ID: 29514797
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-Mediated miR-433 Expression on Exosomes Promotes Bystander Senescence in Multiple Myeloma Cells in a DDR-Independent Manner.
Vulpis E; Cuollo L; Borrelli C; Antonangeli F; Masuelli L; Cippitelli M; Fionda C; Caracciolo G; Petrucci MT; Santoni A; Zingoni A; Soriani A
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047835
[TBL] [Abstract][Full Text] [Related]
8. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
9. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.
Ng S; Deng J; Chinnadurai R; Yuan S; Pennati A; Galipeau J
Cancer Res; 2016 Oct; 76(19):5683-5695. PubMed ID: 27488533
[TBL] [Abstract][Full Text] [Related]
11. IL15 promotes growth and invasion of endometrial stromal cells and inhibits killing activity of NK cells in endometriosis.
Yu JJ; Sun HT; Zhang ZF; Shi RX; Liu LB; Shang WQ; Wei CY; Chang KK; Shao J; Wang MY; Li MQ
Reproduction; 2016 Aug; 152(2):151-60. PubMed ID: 27190213
[TBL] [Abstract][Full Text] [Related]
12. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
Jiang W; Zhang C; Tian Z; Zhang J
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
[TBL] [Abstract][Full Text] [Related]
13. Senescent cells: Living or dying is a matter of NK cells.
Antonangeli F; Zingoni A; Soriani A; Santoni A
J Leukoc Biol; 2019 Jun; 105(6):1275-1283. PubMed ID: 30811627
[TBL] [Abstract][Full Text] [Related]
14. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy.
Zhang J; Sun R; Wei H; Zhang J; Tian Z
Haematologica; 2004 Mar; 89(3):338-47. PubMed ID: 15020274
[TBL] [Abstract][Full Text] [Related]
15. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
[TBL] [Abstract][Full Text] [Related]
16. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.
Jaime-Ramirez AC; McMichael E; Kondadasula S; Skinner CC; Mundy-Bosse BL; Luedke E; Jones NB; Mani A; Roda J; Karpa V; Li H; Li J; Elavazhagan S; La Perle KM; Schmitt AC; Lu Y; Zhang X; Pan X; Mao H; Davis M; Jarjoura D; Butchar JP; Poi M; Phelps M; Tridandapani S; Byrd JC; Caligiuri MA; Lee RJ; Carson WE
Cancer Immunol Res; 2016 Apr; 4(4):323-336. PubMed ID: 26865456
[TBL] [Abstract][Full Text] [Related]
17. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.
Sim GC; Liu C; Wang E; Liu H; Creasy C; Dai Z; Overwijk WW; Roszik J; Marincola F; Hwu P; Grimm E; Radvanyi L
Cancer Immunol Res; 2016 Nov; 4(11):983-994. PubMed ID: 27697858
[TBL] [Abstract][Full Text] [Related]
18. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
[TBL] [Abstract][Full Text] [Related]
20. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
Jungkunz-Stier I; Zekl M; Stühmer T; Einsele H; Seggewiss-Bernhardt R
Leuk Lymphoma; 2014 Jan; 55(1):168-76. PubMed ID: 23573828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
